top of page

Differentiated Antibodies
Multispecifics Design

Trican Biotechnology focuses on the construct and development of innovative therapeutic modalities that address unmet medical needs.

Home

History

Trican Biotechnology, founded in 2015, is designing antibodies based on in vitro and in silico tools for in vivo validation. Through open technology integration with our proprietary platform, Trican delivers differentiated antibodies to address disease setting across oncology, immunology, and ophthalmology.  

We are actively partnering globally with antibody-drug conjugates (ADCs), drug delivery, and bispecific/multispecific innovators.
 

Fully-Human IgG theopoetical antibody discovery

Vision

Innovation, Integrity, Compassion

Guided by the beliefs for innovation, integrity, and compassion for all humanity, Trican Biotechnology strives to continuously advance our antibody engineering platform for speed and quality. We are singularly focused on driving forward novel antibody-based innovations to clinical studies. No one company can do everything.  Thus, we aim to create candidates in collaboration that address unmet medical needs, improve the quality of life for patients, and create value for all stakeholders in the innovation ecosystem. 

SERAbody Platform

Briefly, Trican Biotechnology harvested and assembled tumor reactive B cell receptors sequences into our proprietary DART library ''Directed and Activated immune Response against Tumors/lesions''. 
Next-gen sequencing revealed more than 200 billion binders from DART with fully-human immunogenetics after recombination. For discovery campaigns Trican applies our proprietary high-throughput selection SERA ''Serially Enriched Recombinant Antibodies'' methodology. 

 

Binders or SERAbodies from DART library by Trican are selected based on diversity, specificity, developability, and finally affinity against targets of interest. Trican engineers can further format and characterize SERAbodies into IgG or multispecifics candidates with targeted functionalities for further clinical development.  

Multiple patents have been granted based on SERAbodies raised by Trican.

DART

DART
''Directed Activated  immune Response against Tumors/lesions''  B-Cell Receptor Library

DART_font
SERA

SERA
''Serially Enriched Recombinant Antibodies'' High-Throughput Selection platform

SERA_font
IgG antibody discovery

Trican's Antibody Discovery Mapping 

SERAbody Portfolio

ID

Construct

Indication

Status

TRB007

bispecific

Ophthalmology

Optioned

TRB817

bispecific

Ophthalmology

Characterization

TRB303

IgG

Oncology

Partnered

TRB824

Bispecific

Oncology

In development

TRB301

IgG

Nephrology

Ready

News

Press Release, Updates, Announments

2025. Jul. 01

Oculinea enters into a research agreement with Trican Biotechnology pipeline

  • Option and license research collaboration includes candidate antibodies generated from Trican’s SERAbody platform

  • Agreement will enable Oculinea to design, develop, and expand its proprietary pipeline of ophthalmology delivery devices with improved safety and tolerability compared to existing marketed products.  

San Francisco, California and New Taipei City, Taiwan

July 1st, 2025

Oculinea, Inc. (hereinafter “Oculinea”) and Trican Biotechnology (“Trican”) based in San Francisco, Ca, and New Taipei City, Taiwan on [Release Date] jointly announced a research collaboration and exclusive option and license agreement to develop a novel ophthalmology implant using antibodies from Trican.

 

The asset under evaluation is a bispecific antibody targeting overexpressed drivers in retinal diseases. Under the terms of the agreed upon collaboration, Oculinea will be responsible for research and development of drug-device products incorporating this antibody.  Trican will support bispecific antibody generation.
 

Financial terms of the collaboration are not disclosed.

 

“We are pleased to enter into a collaboration agreement with Oculinea with its proprietary ophthalmology delivery platform,” said Sharon Wang, GM of Trican. “This agreement is the beginning with Oculinea to combine the speed and quality from our antibody discovery with biodegradable and biocompatible sustained release delivery for differentiated first and best-in class drug-devices lowering treatment burden for aging populations.”

 

“We are pleased to enter into a research and discovery partnership with Trican as we continue to expand our efforts to lower treatment burden for patients suffering from degenerative retinal diseases” said Robert Bhisitkul, MD PhD, Professor of Ophthalmology, University of California, San Francisco (UCSF) and cofounder of Oculinea. “With this partnership we look forward to evaluating and bringing innovative products into the clinic by combining Trican’s unique antibodies with Oculinea’s best in class long acting drug delivery platform,” said Murty Vyakarnam, PhD, CEO of Oculinea.

 

About Oculinea, Inc

Oculinea, Inc is an ocular drug delivery company with a unique zero-order drug delivery technology licensed from University of California, San Francisco (UCSF). Oculinea is developing proprietary long-acting drug-device bioresorbable implants capable of delivering both small molecules and biologics based on its Miniaturized Injectable Delivery System (MIDS) platform. Oculinea is actively seeking partnerships with strategics to bring innovative products in ophthalmology for better clinical outcomes and lowering treatment burden for patients.

 

About Trican Biotechnology

Trican Biotechnology, founded in 2015, focuses on multispecific asset discovery and design with ex vivo SERAbodies (Sequentially Enriched Recombinant Antibodies) engineering platform from the proprietary fully-human DART (Directed Antibody Response against Tumors/lesions) library with deep somatically hypermutated affinity, diversity, specificity, and developability against targets of interest.  Trican is actively partnering SERAbodies globally for internal development or external discoveries.

Services / Partnership

Pharmaceutical Research

  • Antibody design & engineering

  • Chemical and medical reagent research

R&D Laboratory

  • Biological testing

  • Bacteriological testing

  • Physicochemical analysis

Process Development

  • Small-scale expression

  • Purification process

  • Formulation process

Druggability Evaluation

  • Physicochemical characteristic

  • Biochemical analysis 

  • Manufacturability

Quality Control

  • Impurity evaluation

  • Bioactivity assay

  • Epitope binning

Consultancy

  • Antibody design & development

  • Scientific research

  • Technical support

Contact

Head Office

24F-7 No.99 Section1, Xintaiwu Road,

Xizhi District, New Taipei City, 221

Tel: +886-2-2697-2685

Fax: +886-2-2697-2015

info@tricanbiotech.com

Inquiries

For any inquiries, questions or commendations, please call: +886-2-2697-2685 or fill out the following form

Employment

To apply for a job with Trican Biotech,

please see detailed information on the 104 website: www.104.com.tw

Success! Message received.

+886-2-2697-2685

24F-7 No.99 Section1, Xintaiwu Road, Xizhi District, New Taipei City, Taiwan

Copyright © 2024 Trican Biotehcnology Inc

bottom of page